



This is a repository copy of *Promoting medication adherence among patients with bipolar disorder: a multicenter randomized controlled trial of a multifaceted intervention.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/115841/>

Version: Accepted Version

---

**Article:**

Pakpour, A.H., Modabbernia, A., Lin, C.-Y. et al. (3 more authors) (2017) Promoting medication adherence among patients with bipolar disorder: a multicenter randomized controlled trial of a multifaceted intervention. *Psychological Medicine*, 47 (14). pp. 2528-2539. ISSN 0033-2917

<https://doi.org/10.1017/S003329171700109X>

---

This article has been published in a revised form in *Psychological Medicine* [<https://doi.org/10.1017/S003329171700109X>]. This version is free to view and download for private research and study only. Not for re-distribution, re-sale or use in derivative works. © Cambridge University Press 2017.

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Promoting medication adherence among patients with bipolar disorder: A multicenter  
randomized controlled trial of a multifaceted intervention**

Amir H Pakpour<sup>1</sup>, Amirhossein Modabbernia<sup>2</sup>, Chung-Ying Lin<sup>3</sup>, Mohsen Saffari<sup>4</sup>, Masoud

Ahmadzad Asl<sup>5</sup>, Thomas L Webb<sup>6</sup>

1 Social Determinants of Health Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.

2 Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

3 Department of Rehabilitation Sciences, Faculty of Health & Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.

4 Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.

5 Mental Health Research Center, Tehran Institute of Psychiatry, School of Behavioral Sciences and Mental Health, Iran University of Medical Sciences, Tehran, IR Iran

6 Department of Psychology, The University of Sheffield, Sheffield, UK.

**Running title: Promoting medication adherence among patients with bipolar disorder**

**Word count: 4684**

**Declaration of Interest: None**

**Address correspondence to:** Dr. Amir H Pakpour, PhD, Associate professor, Social Determinants of Health Research Center, Qazvin University of Medical Sciences, Shahid Bahonar BLV, Qazvin, 3419759811, Iran. Pakpour\_Amir@yahoo.com.

## Abstract

**Background:** The present research aimed to investigate the efficacy of a multifaceted intervention that included motivational interviewing and psychoeducation in improving medication adherence among patients with bipolar disorder.

**Method:** A multicenter, cluster randomized, observer-blind, controlled, parallel-group trial was conducted in ten academic centers in Iran. Patients with BD were randomly assigned to the experimental group (EXP; n=136) or the usual care group (UC; n=134). The EXP group received five sessions of motivational interviewing and psychoeducation together with their family members. The primary outcome measure was changes in scores on the Medication Adherence Rating Scale (MARS) from baseline to 6-months post-intervention. Other outcome measures included serum levels of mood stabilizers, clinical symptoms, quality of life, as well as measures of intention, beliefs about medicine, perceived behavioral control, automaticity, action and coping planning, and adverse reactions.

**Results:** Medication adherence improved over time in both groups, but patients in the EXP group improved more (baseline score: 6.03; score at the sixth month: 9.55) than patients in the UC group (baseline score: 6.17; score at the sixth month: 6.67). In addition, patients in the EXP group showed greater improvement than patients in the UC group in almost all secondary outcomes 6 months following the intervention.

**Conclusions:** Multifaceted interventions that include motivational-interviewing and psychoeducation can significantly improve medication adherence and clinical and functional outcomes in patients with BD.

**Trial Registration Number:** The trial was registered with theClinicalTrials.gov database (NCT02241863) <https://clinicaltrials.gov/ct2/show/NCT02241863>

**Keywords:** adherence; bipolar disorder; mood stabilizer; motivational interviewing;  
psychoeducation

## Introduction

Bipolar disorder (BD) causes significant disability in personal and social domains, and with a prevalence of 1-2% (Merikangas *et al.*, 2007), it imposes a huge burden on society. According to a recent meta-analysis, patients with BD spend more than 40% of their time ill (Forte *et al.*, 2015). Despite the fact that it is possible to control the symptoms of BD using medication, low levels of adherence is a substantial problem and have been reported in up to 50% of cases (Geddes and Miklowitz, 2013, Lacro *et al.*, 2002, Lingam and Scott, 2002, Scott and Pope, 2002a, b). Patients with BD show a much lower rate of routinely and consciously taking prescribed medicines (35%) than patients with, for example, schizophrenia (50-60%). Consequently, patients with BD tend to have poorer health outcomes, including lower levels of daily functioning, psychological health, and quality of life (QoL) (Dean *et al.*, 2004, IsHak *et al.*, 2012). Therefore, it is important to develop interventions that can promote medication adherence (MA).

Effective interventions are likely to be those that target modifiable determinants of non-adherence (Berk *et al.*, 2004), such as beliefs and attitudes (Berk *et al.*, 2004, Lingam and Scott, 2002, Scott and Pope, 2002a). As a result, a few studies (Bauer *et al.*, 2006a, b, Cakir *et al.*, 2009, Javadpour *et al.*, 2013) have designed behavioral interventions (e.g., behavioral therapy, family reliant treatments, psychosocial education, and interpersonal therapies) in an effort to promote MA. For example, Parsons *et al.* used behavioral therapy to improve MA in HIV-positive people and found reductions in substance abuse (although no significant change in MA, perhaps due to the relatively small sample, (Folco *et al.*, 2012). In another study on BD patients, eight sessions of psychoeducation yielded better MA and also QoL among participants in the intervention group when followed up 2 years later (Javadpour *et al.*, 2013). Other interventions

designed to promote MA have focused on increasing communication and support provided by family members to patients, and this strategy is popular for the treatment of mental disorders such as schizophrenia (Rollnick *et al.*, 2008).

However, previous studies that have addressed the challenge of MA in patients with BD have been somewhat limited in their methods. To the best of our knowledge, all previous studies have only used one type of intervention (namely, psychoeducation) in addition to usual care (Rouget and Aubry, 2007). The beneficial effects of psychoeducation for patients with BD have been demonstrated on a number of different outcomes, including MA, insight improvement, and a reduction in symptoms relief for people with BD (Bilderbeck *et al.*, 2016, Hidalgo-Mazzei *et al.*, 2016, Kallestad *et al.*, 2016, Rouget and Aubry, 2007). Similar interventions have also been shown to reduce the burden of care, as well as distress among family members (Bermúdez-Ampudia *et al.*, 2016, Hubbard *et al.*, 2016). Given that patients with BD can differ in their responses to the same intervention (Culpepper, 2014), it is possible that a multifaceted intervention that targets various reasons for non-adherence might result in even better outcomes.

A second problem with the evidence-base to date is that many (but not all) previous studies (Bauer *et al.*, 2006b, Cakir *et al.*, 2009, Javadpour *et al.*, 2013) have primarily used self-reported questionnaires to measure MA. However, self-reported outcomes may be biased by social desirability effects (e.g., patients with BD may feel obligated to report that they have followed the instructions of a health professional) and / or memory problems (e.g., patients with BD may not remember whether they have taken their medication). Using objective measures of adherence, such as serum levels of mood stabilizers, can reduce the possibility of bias and provide a more accurate estimate of the effect of an intervention on MA.

## **The Present Research**

Given the importance of developing interventions to promote MA among people with BD and the limitations of the current evidence, the present research sought to develop a multifaceted intervention and examine the effects of the intervention on self-report and objective indices of MA, as well as secondary outcomes that include potential mediators of treatment effects. The intervention was centered around motivational interviewing (MI), a client-centered approach that seeks to change attitudes and behavior (Lundahl *et al.*, 2013). Although originally developed for reducing alcohol dependence, the use of MI has been rapidly expanded to other health-related domains. Indeed, a meta-analysis of 48 studies has shown that MI is an effective way to promote changes in behavior across multiple healthcare domains such as diabetes, obesity, smoking, and HIV treatment (Lundahl *et al.*, 2013). In recent years, MI has also been used to improve MA in conditions that require long-term commitment to treatment such as schizophrenia and acute coronary syndrome (Depp *et al.*, 2007). Nevertheless, there is scant evidence on the effect of MI in improving MA in patients with BD.

In addition to MI, we also investigated the idea that interventions might benefit from including family members, because family members are likely to support patients with BD in taking their medications (Williams and Wright, 2014) especially in the East, where culture substantially values the family relationship (Tsai *et al.*, 2015).

Despite the importance of MA (or lack thereof) in patients with BD, a systematic review of studies testing the efficacy of interventions designed to improve MA in BD found only five studies whose primary outcome was adherence. A meta-analysis of 18 studies showed an OR of 2.27(95%CI=1.45–3.56) for improvement in adherence in the intervention group compared to control groups (MacDonald *et al.*, 2016). To the best of our knowledge, our study is the most

comprehensive study to date of a multifaceted intervention to improve the adherence in patients with BD.

## **Methods**

### *Design and study population*

A multicenter, randomized, observer-blind, controlled, parallel-group trial was conducted in ten academic centers in Iran: Tehran (three centers), Qazvin, Ahvaz, Semnan, Zanjan, Tabriz, Zahedan, and Mashhad between September 2014 and October 2016. Persian speaking patients were eligible if they; 1) met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for bipolar I or II disorder simultaneously confirmed by the administration of Structured Clinical Interview (SCID); 2) were 18 years or older; 3) were being treated with a mood stabilizer; and 4) were not attending weekly or biweekly psychotherapy. Patients were excluded if they; 1) had a DSM-IV-TR diagnosis of drug or alcohol misuse disorders (five independent researchers administered a semi-structured interview and a structured interview based on DSM-IV-TR criteria for alcohol abuse, alcohol dependence and also substance abuse excluding nicotine); 2) showed evidence of severe DSM-IV-TR borderline personality; 3) needed to change the type and/or the dose of a mood stabilizer; 4) were pregnant or planned to be pregnant in the next year; 5) were unable and/or unwilling to provide a written informed consent; 6) had any organic cerebral cause for bipolar disorder (e.g., multiple sclerosis or stroke); or 7) had an intellectual disability. Figure 1 shows the flow of participants through the trial, including the number of patients excluded for the various reasons detailed above.

All patients and their family members provided informed consent before participating in the study. The protocol was prepared in accordance with the Ottawa Statement, the Helsinki Declaration and Good Clinical Practice, and ethical review committees at each of the sites



approved the trial. The trial was registered in the clinicaltrials.gov registry (<https://clinicaltrials.gov/ct2/show/NCT02241863>).

### *Intervention*

A multifaceted intervention was developed in an effort to improve MA and clinical outcomes. The intervention included two components: a) Psychoeducation for the patients and their family members and b) motivational interviewing. Detailed information on the intervention is provided in the online supplementary materials.

### *MI integrity/fidelity*

To assess treatment fidelity, all sessions were recorded and transcribed. Two trained research assistants reviewed each recording in order to determine the proportion of the intervention elements that were covered by the facilitators. The Motivational Interview Treatment Integrity (MITI) scale was used to assess the integrity of the MI in the EXP group. Two separate aspects of treatment fidelity were taken into account: (i) Global variables (i.e., empathy, evocation, collaboration, autonomy/support, and direction) and (ii) behavior counts (i.e., giving information, asking open-ended and closed-ended questions, providing simple and complex reflections, and making other statements categorized as MI adherent or not). Inter-rater reliability was computed using intraclass correlation coefficients (ICCs) in a two-way mixed model with absolute agreement. The ICCs were found to be adequate for global measures, behavior counts, and summary scores (ICCs ranged from 0.69 to 0.92, as reported in online Supplementary Table S1).

### *Usual Care*

Patients in the usual care (UC) group received the usual care that is provided to people with severe mental illnesses in Iran, which is mainly based on pharmacological interventions and

follow-up visits to address and deal with adjustments to the dosage and / or nature of medications and management of side effects. There are no national guidelines for the provision of psychosocial services such as occupational rehabilitation, supported employment, social skills education and family support. However, during last decade, there has been a growing interest in providing these services, such that informal psycho-education about social skills and compliance with treatment may be provided on some occasions.

### ***Outcomes***

The primary outcome measure was medication adherence (MA) measured using self-report and objective indices. Secondary outcomes included measures of beliefs and psychosocial health. All outcomes were measured three times (at baseline before the intervention, and then one and six months after the intervention) using the measures described below. Clinical status was assessed using the Clinical Global Impressions-Bipolar-Severity of Illness (CGI-BP-S; (Spearing *et al.*, 1997) and the Young Mania Rating Scale (YMRS; (Young *et al.*, 1978) and the Montgomery Åsberg Depression Rating Scale (MADRS; (Montgomery and Asberg, 1979) were used to assess manic and depressive symptoms, respectively. The clinical measures were administered by five psychiatrists who were blinded to the treatment allocation.

#### ***Medication Adherence Rating Scale (MARS)***

The MARS was used to measure the primary outcome in the study; namely, MA. Patients were asked to rate the extent to which five statements describing non-adherent behaviors, such as forgetting to take medicines or missing a dose, apply to them on a 5-point Likert scale (1: *Always* to 5: *Never*) e.g., *Do you ever forget to take your medication?* (O'Carroll *et al.*, 2011). The MARS has been shown to be relatively unaffected by social desirability effects (O'Carroll *et al.*,

2011), and the Persian translation of the MARS (Pakpour *et al.*, 2014) demonstrates unidimensionality and high levels of internal consistency (Cronbach's  $\alpha=0.84$ ).

#### *Plasma level of mood stabilizer*

The primary outcome of MA was also assessed using objective indices. Specifically, plasma levels of mood stabilizers were obtained from biochemistry laboratories at each center, and levels of three mood stabilizers were assayed: Lithium, Carbamazepine, and Sodium valproate.

#### *Beliefs about Medicines Questionnaire - Specific (BMQ-Specific)*

The BMQ-specific (Horne *et al.*, 1999) was used to assess beliefs about medications prescribed for personal use and has been shown to be correlated to adherence (Pakpour *et al.*, 2015). The measure reflects two domains (necessity and concerns) and each domain is assessed using five items that patients are asked to indicate their agreement with on a 5-point Likert scale (from 1: *strongly disagree* to 5: *strongly agree*). The necessity domain assesses patients' beliefs about the necessity of the medication (e.g., *Without my medicines I would be very ill*), while the concerns domain examines patients' beliefs about the possible adverse effects of the medication (e.g., *Having to take medicines worries me*). Scores can range between 5 and 25, with higher scores indicating stronger beliefs about the necessity of the medication or a higher level of concern about taking the medicine, respectively. The Persian version of the BMQ has promising psychometric properties and has been used to assess beliefs about medications among an Iranian sample with diabetes (Aflakseir, 2012).

#### *Intention*

Patients' intention to take their medication was measured using a questionnaire adapted from Pakpour *et al.* (Pakpour *et al.*, 2014). Patients were asked to indicate their agreement with

five statements (e.g., *I intend to take regular medication in the future*) on a 5-point Likert scale (1: *completely disagree* to 5: *completely agree*). Internal consistency of the scale was adequate (Cronbach's  $\alpha=0.91$ ).

#### *Self-monitoring*

Self-monitoring was measured by three items (e.g., *During the last week, I have consistently monitored when to take my medications*, on a 5-point scale from *not at all true* (1) to *exactly true* (5) (Pakpour *et al.*, 2015). Cronbach's  $\alpha$  for the scale was 0.89.

#### *Self-report Behavioral Automaticity Index (SRBAI)*

The SRBAI comprises four items from Self-Report Habit Index (Gardner *et al.*, 2012), that measure the extent to which relevant behaviors are performed automatically (a key component of habit, (Orbell and Verplanken, 2010). Each item starts with the stem *Behavior X is something...* and is followed by (1) *I do automatically*; (2) *I do without having to consciously remember*; (3) *I do without thinking*; and (4) *I start doing before I realize I am doing it* (Gardner *et al.*, 2012). All items were rated on a 5-point Likert scale (1: *disagree* to 5: *agree*).

#### *Action and coping planning*

Action planning was measured using four items: *I have made a detailed plan regarding when / where / how often / how to take medication*. Similarly, coping planning was measured using four items: *I have made a detailed plan regarding...* (1) *what to do if something interferes*; (2) *what to do if I forget to take my medication*; (3) *how to motivate myself if I don't feel like taking my medication*; and (4) *how to prevent myself from being distracted*. All items measuring action planning and coping planning were rated on a 5-point Likert scale (1: *completely disagree* to 5: *completely agree*) and showed high levels of internal consistency in the present research (Cronbach's  $\alpha=0.90$ ).

### *Perceived behavioral control (PBC)*

PBC was measured using four items on a 5-point Likert scale (1: *completely disagree* to 5: *completely agree*) that have proved internally consistent in the present research (Cronbach's  $\alpha = 0.94$ ). Sample items include: *For me to take regular medication in the future is...* and *It is up to me to take regular medication...*

### *Young Mania Rating Scale (YMRS)*

The YMRS contains 11 items each describing a specific mania syndrome. Clinicians were asked to rate how severely the patients have experienced each syndrome within the past 2 days. The items include elevated mood, increased motor and activity-energy, sexual interest, sleep, irritability, speech rate and amount, language/thought disorder, thought content, disruptive/aggressive behavior, appearance, and insight. All items were rated from 0 (absent) to 4 (the highest level), and four of the items (irritability, speech, thought content, and disruptive/aggressive behavior) were double-weighted (McIntyre *et al.*, 2004, Young *et al.*, 1978) when computing the overall score.

### *Montgomery Åsberg Depression Rating Scale (MADRS)*

The MADRS contains 10-items designed to measure indicators of depression (e.g., reduced appetite). The MADRS is designed to be particularly sensitive to the effects of treatment (such as antidepressants) among people with mood disorders. Clinicians were asked to respond to each of the items on a 7-point scale and total scores could range from 0 (no symptoms of depression) to 60 (highest level of depression (Montgomery and Asberg, 1979).

### *Clinical Global Impressions-Bipolar-Severity of Illness (CGI-BP-S)*

The CGI-BP-S is modified from Clinical Global Impressions Scale for specific use with patients with BD. The CGI-BP-S comprised three measures to which clinicians were asked to

respond using a 7-point Likert scale. The measures evaluated: (1) The severity of illness (*Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?*); (2) change from preceding phase (*Compared to the phase immediately preceding this trial, how much has the patient changed?*); (3) change from worst phase (*Compared to the patient's worst phase of illness prior to the current medication trial or during the early titration phase, how much has the patients changed?*). A lower score on the CGI-BP-S suggests a better condition (Spearing *et al.*, 1997)

#### *Quality of Life in Bipolar Disorder scale (QoL.BD)*

The QoL.BD contains 12 items and is designed to capture patients' subjective perceptions of BD-specific QoL. Each item asks about a specific experience in the past week (e.g., *Felt physically well*). Patients are asked to respond on a 5-point Likert scale (1: *strongly agree* to 5: *strongly disagree*), and a higher score represents a higher level of QoL (Michalak *et al.*, 2010).

#### *Adverse drug reaction (ADR)*

Adverse reactions to the prescribed medications were assessed using a questionnaire adapted from the clinical monitoring form for mood disorders (Sachs *et al.*, 2002). Patients were asked to indicate the severity of nine side effects (e.g., tremor, dry mouth, etc.) on a five-point Likert scale, ranging from *none* (0) to *severe* (4). A total score was computed as the sum of the severity of each side effect and could range from 0 to 36 with higher scores indicating more severe side effects.

#### ***Randomization and masking***

In order to prevent contamination between the EXP and UC groups, centers were used as unit of randomization rather than patients. Trained professionals at each center (e.g., physicians

and nurses) enrolled participants. Centers were allocated in a 1:1 ratio to either the EXP or UC groups by a computer-generated list of random numbers. Five clusters were assigned to the EXP group and 5 clusters to the UC group. Figure 1 illustrates the allocation to condition and the flow of participants through the trial.

Across centers, 538 patients were referred to the trial: 43 declined to be screened for eligibility, 217 did not meet screening criteria, and we lost contact with 8. A total of 270 patients underwent baseline assessment and 134 were randomized to the UC group and 136 to the EXP group. As a result, each center recruited an average of 26 patients. Assessors, psychologists, and psychiatrists were blind to the intervention status of the participants.

### ***Sample Size***

The required sample size was calculated based on the primary outcome measure (the MARS). It was estimated that 132 patients would be needed in each condition to detect an effect size of *1 point in the MARS*, with 85% power and a significance level of 5%, assuming an intracluster correlation coefficient of 0.05, a mean cluster size equal to 27, and that 10% of the patients would likely be lost to follow up.

### ***Statistical Analysis***

Due to the hierarchical nature of the data (i.e., patients were nested within centers), we used multilevel linear mixed modeling to investigate the efficacy of the intervention. Three levels of analysis – time, patients, and centers – were estimated with a restricted iterative generalized least square (RIGLS) estimation. Therefore, for each model, three fixed effects were entered; an intercept term, Time and condition (the UC group served as the reference group).

To decompose the interaction between condition and time, we compared the effects of condition at each time point (i.e., one and six months after treatment) on each dependent

variable. The Benjamini and Hochberg false discovery rate was used to adjust p-values for multiple comparisons. In addition, Krull and MacKinnon's three-step recommendations for conducting mediation analyses were performed to identify potential mediators of treatment effects (Krull and MacKinnon, 1999). All tests were two sided with a significance level of <0.05 and analyses were performed on an intent-to-treat basis using MLwiN 2.27 software.

## **Results**

### **Randomization Check**

Table 1 summarizes the baseline and clinical characteristics of the two groups. About 51% of the participants in the UC group and 55% of the participants in the EXP group were females and the mean age of the patients was 41.2 (6.4) years in the UC group and 41.8 (8.4) in the EXP group. The mean age of onset of BD was 24 years for both groups.

### **Effects of the Intervention on the Primary Outcome: Medication Adherence**

Table 2 provides the descriptive statistics for all outcome measures by condition and time. Tables 3 and 4 show the findings of three-level multiple linear regression models examining the effect of the intervention on outcomes. MA improved over time in both the EXP and UC groups. However, scores on the MARS indicated a greater improvement in MA among patients in the EXP group:  $M_{\text{baseline}} = 6.03$  ( $SD = 2.56$ ) and  $M_{\text{six months}} = 9.55$  ( $SD = 3.88$ ); than among patients in the UC group:  $M_{\text{baseline}} = 6.17$  ( $SD = 2.90$ ) and  $M_{\text{six months}} = 6.67$  ( $SD = 2.93$ ). In support of this idea, after taking into account the study center and repeated measurement over time, our multilevel mixed models showed that patients in the EXP group had significantly higher MARS scores than did patients in the UC group both one ( $B=3.15$ ;  $p<0.001$ ) and six months ( $B=3.20$ ;  $p<0.001$ ) after the intervention (Table 3).



Analysis of the objective measures of MA; namely, plasma level of mood stabilizers, indicated that patients in the UC group had slightly decreased levels of Lithium (baseline: 0.660 mmol/L; six month: 0.596 mmol/L), Carbamazepine (baseline: 5.580 mcg/mL; six month: 5.472 mcg/mL), and Sodium valproate (baseline: 41.255 mcg/mL, six month: 41.001 mcg/mL) at six months post-intervention, suggesting that they may not have been adhering to their medication regimen. In contrast, patients in the EXP group had increased levels of Lithium (baseline: 0.665 mmol/L; six month: 0.698 mmol/L), Carbamazepine (baseline: 5.596 mcg/mL; six month: 6.147 mcg/mL), and Sodium valproate (baseline: 40.094 mcg/mL; six month: 43.048 mcg/mL), supporting the beneficial effects of the intervention on MA suggested by the self-report measure of adherence. After controlling for study center and repeated measurement, patients in the EXP group had significantly higher plasma levels of mood stabilizers than did patients in the UC group at one month ( $B = 0.108$  for Lithium, 1.53 for Carbamazepine, and 3.62 for Sodium valproate;  $p < 0.001$ ), and six months ( $B = 0.178$  for Lithium, 1.40 for Carbamazepine, and 5.28 for Sodium valproate;  $p < 0.001$ ) post-intervention (see Supplementary Table S2).

### **Effects of the Intervention on Secondary Outcomes**

Almost all secondary outcomes improved over time in the EXP group (see Table 2), and the findings of multiple linear regression models (reported in Tables 3 and 4) show that patients in the EXP group had significantly better outcomes on all secondary measures one month and six months after the intervention, compared with patients in the UC group, except for the measure of quality of life at one month follow-up. Therefore, patients in the EXP group had stronger intentions to take their medication, believe that they had more control over so doing, that taking their medication was more automatic, and were more likely to form action and coping plans to promote MA.

There was also evidence of a decrease in clinical symptoms among patients in the EXP group, relative to patients in the UC group, as shown by significant effects of group on the YMRS ( $B=-5.32$ ;  $p<0.001$ ), CGI-BP-S ( $B=-0.528$ ;  $p<0.001$ ), and MARDS ( $B=-4.54$ ;  $p<0.001$ ). Furthermore, the quality of life of patients in the EXP group improved significantly more than among patients in the UC group ( $B=1.17$ ;  $p=0.025$ ).

### **Mediation Analyses**

Table S3 in the supplementary materials shows the direct and mediated effects of group on MA and quality of life (QoL). The effect of the intervention on self-reported MA were mediated by changes in beliefs about medication (i.e., beliefs about the necessity of taking the medication and concern about the possible adverse effects of the medication), intention, self-monitoring, action planning, and coping planning. In turn, MA mediated the effect of the intervention on QoL.

We also examined whether self-reported MA (i.e., scores on the MARS) mediated the effect of the intervention on plasma levels of mood stabilizers. The results of the mediation analysis indicated that self-reported MA mediated the effect of the intervention on improvements in plasma levels of mood stabilizers. Specifically, scores on the MARS mediated the effect of the intervention effect on improvements in Serum Lithium levels at one month ( $B= 0.32$ ;  $SE= 0.10$ ;  $p<0.001$ ) and six month ( $B= 0.42$ ;  $SE= 0.07$ ;  $p<0.001$ ) follow-ups, improvements in Serum Carbamazepine levels at one month ( $B= 2.46$ ;  $SE= 0.36$ ;  $p<0.001$ ) and six month ( $B= 2.59$ ;  $SE= 0.49$ ;  $p<0.001$ ) follow-ups, and on improvements in Serum Sodium Valproate levels at one month ( $B= 2.17$ ;  $SE= 0.68$ ;  $p<0.001$ ) and six month ( $B= 1.92$ ;  $SE= 0.62$ ;  $p<0.001$ ) follow-ups.

### **Discussion**

The aim of the present research was to assess the efficacy of a multifaceted intervention on MA and health outcomes in patients with BD. We found that a combination of brief sessions of MI, together with psychoeducation and efforts to engage family members in promoting adherence led to significant improvements in objective and self-report measures of MA, as well as in various clinical and functional outcomes compared with usual care. As such, we hope that the findings are informative to mental health clinicians seeking to promote MA among patients with BD and provide a rationale for designing and implementing multifaceted interventions to improve MA in such patients.

A few prior studies have investigated whether interventions based on MI can improve MA in patients with BD. In a quasi-experimental pilot study of 21 elderly subjects with BD, Depp et al. showed that a multifaceted intervention including motivational training improved MA, as well as depressive symptoms and QoL (Depp *et al.*, 2007). However, this was only a preliminary pilot study with a simple training intervention and a limited outcome measure. Another study on patients with BD in Iran, showed the effectiveness of an intervention based on psychoeducation. This study included an 18 month follow up and measured quality of life, medication compliance as well as frequency of hospitalization showing considerable improvements in each outcome (Javadpour *et al.*, 2013). However, the study only involved one center with 108 patients the intervention only used psychoeducation and did not include family members.

In addition to MI, our intervention included other components, namely psychoeducation and engagement of a family member. We found promising effects of the intervention on both self-reported and objective measures of MA. Furthermore, our findings also pointed to

improvements in symptoms and QoL, which mediation analyses indicated can be attributed to improved MA.

### **Strengths and limitations**

The present research had several strengths. First, we used both self-report and objective outcome measures to ensure the validity of our findings. Second, using multiple outcome measures targeting different domains allowed us to look at the effect of the intervention on different aspects of health and functioning. Third, we used a multilevel linear mixed model to evaluate the effect of intervention on outcomes.

Our findings should be interpreted in light of some limitations, however. First, family engagement constituted an important component of the intervention in the present research. While we deem this to be a strength of our multifaceted approach, we acknowledge that family likely plays a more significant role in individuals who live in Middle Eastern cultures than in other, more Western societies (Daneshpour, 1998). Therefore, the effect of the family component of our intervention might not necessarily be generalizable to other cultures. Second, we did not assess the effect of our intervention beyond six months of follow-up. However, a meta-analysis by MacDonald and colleagues showed that the effects of interventions on MA seemed to be durable for up to two years (MacDonald *et al.*, 2016). There is no reason to believe that the effects of the present intervention might not also be maintained over this period. Third, it might be argued that a longer intervention might improve adherence rates even further. However, the feasibility of interventions should be considered in term of time and cost as well as efficacy as longer interventions may require greater investment of resources for a relatively small improvement in outcomes. Finally, a natural downside to a multifaceted approach to intervention is that it is difficult to isolate which part of the intervention was most effective. Future research

might usefully adopt factorial designs that systematically manipulate and compare different components of the intervention (e.g., the intervention with and without family support) in an effort to identify the active ingredients.

### **Conclusion**

The present findings provide robust evidence that a multifaceted intervention based on MI, psychoeducation, and attempts to engage family members can improve MA among patients with BD. The implication is that health care professionals, especially those who deal with mental health aspects of people with psychiatric disorders such as BD, may use our findings to improve MA and adjust clinical symptoms in their clients.

## References

- Aflakseir, A.** (2012). Role of illness and medication perceptions on adherence to medication in a group of Iranian patients with type 2 diabetes. *Journal of Diabetes***4**, 243-7.
- Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., Sajatovic, M. & Cooperative Studies Program 430 Study, T.** (2006a). Collaborative care for bipolar disorder: part I. Intervention and implementation in a randomized effectiveness trial. *Psychiatric services***57**, 927-36.
- Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., Sajatovic, M. & Cooperative Studies Program 430 Study, T.** (2006b). Collaborative care for bipolar disorder: Part II. Impact on clinical outcome, function, and costs. *Psychiatric services* **57**, 937-45.
- Berk, M., Berk, L. & Castle, D.** (2004). A collaborative approach to the treatment alliance in bipolar disorder. *Bipolar disorders***6**, 504-18.
- Bermúdez-Ampudia, C., García-Alocén, A., Martínez-Cengotitabengoa, M., Alberich, S., González-Ortega, I., Resa, S. B. & González-Pinto, A.** (2016). Mixed-effects models: Family burden and functionality in patients with bipolar disorder. *European Psychiatry***33**, S331.
- Bilderbeck, A. C., Atkinson, L. Z., McMahon, H. C., Voysey, M., Simon, J., Price, J., Rendell, J., Hinds, C., Geddes, J. R., Holmes, E. & Miklowitz, D. J.** (2016). Psychoeducation and online mood tracking for patients with bipolar disorder: A randomised controlled trial. *Journal of Affective Disorders* **205**, 245-51.
- Cakir, S., Bensusan, R., Akca, Z. K. & Yazici, O.** (2009). Does a psychoeducational approach reach targeted patients with bipolar disorder? *Journal of Affective Disorders***119**, 190-3.
- Culpepper, L.** (2014). The diagnosis and treatment of bipolar disorder: decision-making in primary care. *primary care companion for CNS disorders***16**,3.
- Daneshpour, M.** (1998). Muslim families and family therapy. *Journal of marital and family therapy***24**, 355-68.
- Dean, B. B., Gerner, D. & Gerner, R. H.** (2004). A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. *Current medical research and opinion* **20**, 139-54.
- Depp, C. A., Lebowitz, B. D., Patterson, T. L., Lacro, J. P. & Jeste, D. V.** (2007). Medication adherence skills training for middle-aged and elderly adults with bipolar disorder: development and pilot study. *Bipolar disorders* **9**, 636-45.
- Folco, E. G., Lee, C.-S., Dufu, K., Yamazaki, T. & Reed, R.** (2012). The Proteins PDIP3 and ZC11A Associate with the Human TREX Complex in an ATP-Dependent Manner and Function in mRNA Export. *PLoS ONE* **7**, e43804.

- Forte, A., Baldessarini, R. J., Tondo, L., Vazquez, G. H., Pompili, M. & Girardi, P.** (2015). Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. *Journal of Affective Disorders* **178**, 71-8.
- Gardner, B., Abraham, C., Lally, P. & de Bruijn, G. J.** (2012). Towards parsimony in habit measurement: testing the convergent and predictive validity of an automaticity subscale of the Self-Report Habit Index. *International Journal of Behavioral Nutrition and Physical Activity* **9**, 102.
- Geddes, J. R. & Miklowitz, D. J.** (2013). Treatment of bipolar disorder. *Lancet* **381**, 1672-82.
- Hidalgo-Mazzei, D., Mateu, A., Reinares, M., Murru, A., del Mar Bonnín, C., Varo, C., Valentí, M., Undurraga, J., Strejilevich, S., Sánchez-Moreno, J. & Vieta, E.** (2016). Psychoeducation in bipolar disorder with a SIMPLE smartphone application: Feasibility, acceptability and satisfaction. *Journal of Affective Disorders* **200**, 58-66.
- Horne, R., Weinman, J. & Hankins, M.** (1999). The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology and health* **14**, 1-24.
- Hubbard, A. A., McEvoy, P. M., Smith, L. & Kane, R. T.** (2016). Brief group psychoeducation for caregivers of individuals with bipolar disorder: A randomized controlled trial. *Journal of Affective Disorders* **200**, 31-36.
- IsHak, W. W., Brown, K., Aye, S. S., Kahloon, M., Mobaraki, S. & Hanna, R.** (2012). Health-related quality of life in bipolar disorder. *Bipolar disorders* **14**, 6-18.
- Javadpour, A., Hedayati, A., Dehbozorgi, G. R. & Azizi, A.** (2013). The impact of a simple individual psycho-education program on quality of life, rate of relapse and medication adherence in bipolar disorder patients. *Asian journal of psychiatry* **6**, 208-13.
- Kallestad, H., Wullum, E., Scott, J., Stiles, T.C & Morken, G.** (2016). The long-term outcomes of an effectiveness trial of group versus individual psychoeducation for bipolar disorders *Journal of Affective Disorders* **15**, 32-38.
- Krull, J. L. & MacKinnon, D. P.** (1999). Multilevel mediation modeling in group-based intervention studies. *Evaluation Review* **23**, 418-44.
- Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G. & Jeste, D. V.** (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. *Journal of Clinical Psychiatry* **63**, 892-909.
- Lingam, R. & Scott, J.** (2002). Treatment non-adherence in affective disorders. *Acta Psychiatrica Scandinavica* **105**, 164-72.
- Lundahl, B., Moleni, T., Burke, B. L., Butters, R., Tollefson, D., Butler, C. & Rollnick, S.** (2013). Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials. *Patient Education and Counseling* **93**, 157-68.

**MacDonald, L., Chapman, S., Syrett, M., Bowskill, R. & Horne, R.** (2016). Improving medication adherence in bipolar disorder: A systematic review and meta-analysis of 30 years of intervention trials. *Journal of Affective Disorders* **194**, 202-21.

**McIntyre, R. S., Mancini, D. A., Srinivasan, J., McCann, S., Konarski, J. Z. & Kennedy, S. H.** (2004). The antidepressant effects of risperidone and olanzapine in bipolar disorder. *Canadian Journal of Clinical Pharmacology* **11**, e218-26.

**Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M., Petukhova, M. & Kessler, R. C.** (2007). Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. *Archives of general psychiatry* **64**, 543-52.

**Michalak, E. E., Murray, G. & Collaborative, R. T. t. S. P. I. i. B. D.** (2010). Development of the QoLBD: a disorder-specific scale to assess quality of life in bipolar disorder. *Bipolar disorders* **12**, 727-40.

**Miller, W. R. & Rollnick, S.** (2012). *Motivational interviewing: helping people change*. Guilford Press.

**Montgomery, S. A. & Asberg, M.** (1979). A new depression scale designed to be sensitive to change. *British Journal of Psychiatry* **134**, 382-9.

**O'Carroll, R., Whittaker, J., Hamilton, B., Johnston, M., Sudlow, C. & Dennis, M.** (2011). Predictors of adherence to secondary preventive medication in stroke patients. *Annals of Behavioral Medicine* **41**, 383-90.

**Orbell, S. & Verplanken, B.** (2010). The automatic component of habit in health behavior: habit as cue-contingent automaticity. *Health Psychology* **29**, 374-83.

**Pakpour, A. H., Gellert, P., Asefzadeh, S., Updegraff, J. A., Molloy, G. J. & Sniehotta, F. F.** (2014). Intention and planning predicting medication adherence following coronary artery bypass graft surgery. *Journal of Psychosomatic Research* **77**, 287-95.

**Pakpour, A. H., Gholami, M., Esmaili, R., Naghibi, S. A., Updegraff, J. A., Molloy, G. J. & Dombrowski, S. U.** (2015). A randomized controlled multimodal behavioral intervention trial for improving antiepileptic drug adherence. *Epilepsy & Behavior* **52**, 133-42.

**Rollnick, S., Miller, W. R., Butler, C. C. & Aloia, M. S.** (2008). *Motivational interviewing in health care: helping patients change behavior*. The Guilford Press: New York.

**Rouget, B. W. & Aubry, J. M.** (2007). Efficacy of psychoeducational approaches on bipolar disorders: a review of the literature. *Journal of Affective Disorders* **98**, 11-27.

**Sachs, G. S., Guille, C. & McMurrich, S. L.** (2002). A clinical monitoring form for mood disorders. *Bipolar disorders* **4**, 323-7.

**Scott, J. & Pope, M.** (2002a). Nonadherence with mood stabilizers: prevalence and predictors. *Journal of Clinical Psychiatry* **63**, 384-90.



**Scott, J. & Pope, M. (2002b).** Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. *Journal of Clinical Psychiatry* **159**, 1927-9.

**Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D. & Nolen, W. (1997).** Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. *Psychiatry Research* **73**, 159-71.

**Tsai, M. C., Strong, C. & Lin, C. Y. (2015).** Effects of pubertal timing on deviant behaviors in Taiwan: A longitudinal analysis of 7th- to 12th-grade adolescents. *Journal of Adolescence* **42**, 87-97.

**Williams, A. A. & Wright, K. S. (2014).** Engaging families through motivational interviewing. *Pediatric Clinics of North America* **61**, 907-21.

**Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. (1978).** A rating scale for mania: reliability, validity and sensitivity. *British Journal of Psychiatry* **133**, 429-35.

## Tables

Table 1: Baseline and Clinical Characteristics of Patients by Condition

	Mean ( <i>SD</i> ) or <i>n</i> (%)	
	Usual care ( <i>n</i> = 136)	Experimental ( <i>n</i> = 134)
Age (year)	41.2 (6.4)	41.8(8.4)
Age at onset (year)	24.3 (6.1)	24.0 (5.9)
Sex		
Male	67 (49.3%)	60 (44.8%)
Female	69 (50.7%)	74 (55.2%)
Education (year)	6.9 (3.4)	6.2 (4.0)
Duration of illness (year)	8.2 (5.6)	8.6 (5.3)
Monthly family income (US\$)		
High (>1000\$)	26 (19.1%)	15 (11.2%)
Intermediate (500-1000\$)	78 (57.4%)	92 (68.7%)
Low (<500\$)	32 (23.5%)	27 (20.1%)
Bipolar disorder type		
I	114 (83.8%)	110 (82.1%)
II	22 (16.2%)	24 (17.9%)
Living status		
Living with partner	57 (41.9%)	52 (38.8%)
Single	79 (58.1%)	82 (61.2%)
Total number of episodes	8.3 (5.7)	8.5 (6.1)
Number of hospitalizations	2.1 (0.49)	2.2 (0.5)
Mood stabilizers (Yes)		
Lithium	57 (41.9%)	56 (41.8%)
Carbamazepine	23 (16.9%)	19 (14.2%)
Sodium valproate	56 (41.2%)	59 (44.0%)
Antipsychotics (Yes)	34 (25.0%)	31 (23.1%)
Mood stabilizer monotherapy (Yes)	58 (42.6%)	54 (40.3%)
Drug dose at inclusion (mg)		
Lithium	980.6 (212.8)	970.1 (200.1)
Carbamazepine	640 (173.2)	651 (171.9)
Sodium valproate	960 (141.9)	958 (134.6)
The total numbers of taking drugs	2.3 (1.0)	2.1 (1.2)
Body mass index (kg/m <sup>2</sup> )	26.8 (4.2)	25.9 (4.0)
Number of centers	5	5
Number of patients in each center	26.6 (3.1)	26.1 (3.4)

*Note.* *SD* = standard deviation.

Table 2: Descriptive Statistics for all Outcome Measures by Condition and Time

Variable	Group	Mean ( <i>SD</i> )/missing n		
		Baseline	One month post-intervention	Six months post-intervention
MARS	UC	6.17 (2.90)/0	6.77 (2.85)/4	6.67 (2.93)/7
	EXP	6.03 (2.56)/0	9.53 (3.84)/1	9.55 (3.88)/9
BMQ necessity	UC	14.59 (2.31)/0	14.52 (2.20)/2	14.54 (3.01)/8
	EXP	14.43 (2.29)/1	18.69 (2.49)/2	18.64 (2.48)/10
BMQ concerns	UC	13.19 (3.97)/0	13.22 (3.92)/4	13.20 (4.13)/12
	EXP	12.90 (3.31)/0	6.04 (3.80)/1	5.90 (3.75)/9
Perceived behavioral control	UC	2.58 (0.92)/4	2.61 (0.95)/3	2.56 (0.97)/8
	EXP	2.55 (0.90)/0	2.86 (1.06)/3	2.89 (1.13)/9
Intention	UC	2.73 (0.65)/0	2.78 (0.69)/3	2.75 (0.71)/10
	EXP	2.79 (0.75)/0	3.45 (1.12)/1	3.43 (1.14)/11
Self-monitoring	UC	1.99 (0.42)/2	1.96 (0.52)/0	1.94 (0.43)/10
	EXP	2.05 (0.53)/1	2.57 (1.03)/2	2.54 (1.01)/12
Action planning	UC	1.91 (0.51)/0	1.89 (0.55)/3	1.86 (0.56)/9
	EXP	1.90 (0.54)/1	2.64 (1.17)/4	2.66 (1.34)/9
Coping planning	UC	1.67 (0.54)/0	1.64 (0.55)/4	1.65 (0.56)/9
	EXP	1.65 (0.59)/1	2.40 (1.28)/5	2.39 (1.39)/9
SRBAI	UC	1.88 (0.82)/0	1.87 (0.83)/2	1.79 (0.88)/8
	EXP	1.90 (0.83)/0	2.14 (0.90)/4	2.20 (0.93)/11
QoL.BD	UC	39.38 (9.18)/0	39.42 (9.26)/3	39.18 (9.27)/9
	EXP	39.14 (11.34)/0	40.90 (11.63)/2	43.56 (12.37)/11
YMRS	UC	15.57 (2.28)/0	15.59 (2.46)/3	15.61 (2.35)/7

	EXP	15.32 (2.76)/0	12.23 (2.19)/1	10.04 (2.01)/9
CGI-BP-S	UC	4.55 (0.65)/0	4.56 (0.61)/2	4.57 (0.47)/7
	EXP	4.60 (0.75)/0	4.52 (0.51)/2	4.18 (0.43)/9
MADRS	UC	21.82 (5.81)/0	21.37 (4.74)/2	21.28 (4.85)/7
	EXP	22.21 (5.71)/0	17.08 (7.67)/3	17.13 (7.55)/9
ADR	UC	10.03 (2.97)/3	10.00 (2.99)/6	9.98 (2.79)/9
	EXP	9.94 (2.95)/4	10.09 (2.88)/3	10.15 (2.89)/12
Serum Lithium level	UC	0.66 (0.15)/0	0.601 (0.22)/2	0.596 (0.227)/4
(mmol/L)	EXP	0.67 (0.18)/0	0.694 (0.23)/1	0.698 (0.241)/2
Serum Carbamazepine level	UC	5.58 (1.40)/0	5.496 (1.39)/2	5.472 (1.461)/1
(mcg/mL)	EXP	5.60 (1.51)/0	5.948 (1.84)/1	6.147 (1.680)/3
Serum Sodium valproate	UC	41.26 (16.45)/0	41.09 (16.73)/2	41.001 (17.746)/4
level (mcg/mL)	EXP	40.90 (18.78)/0	42.55 (18.19)/0	43.048 (19.224)/3

*Note.* *SD* = standard deviation. UC = usual care group. EXP = experimental group. BMQ = Beliefs about Medicines Questionnaire. SRBAI = Self-report Behavioral Automaticity Index. MARS = Medication Adherence Rating Scale. QoL.BD = Quality of Life in Bipolar Disorder scale. YMRS = Young Mania Rating Scale. CGI-BP-S = Clinical Global Impressions-Bipolar-Severity of Illness. MADRS = Montgomery-Åsberg Depression Rating Scale. ADR = Adverse drug reaction or adverse drug effect.

Table 3: Three-level Multiple Linear Regression Models predicting Medication Adherence, Intention, Perceived Behavioral Control, Automaticity of Medication Taking, Self-Monitoring, Action and Coping Planning

Variable	MARS		INT		PBC		SRBAI		SM		ACP		CP	
	<i>B (SE)</i>	<i>P</i> -value	<i>B (SE)</i>	<i>P</i> -value	<i>B (SE)</i>	<i>P</i> -value	<i>B (SE)</i>	<i>P</i> -value	<i>B (SE)</i>	<i>P</i> -value	<i>B (SE)</i>	<i>P</i> -value	<i>B (SE)</i>	<i>P</i> -value
Group (Ref: UC)	0.69 (0.61)	0.26	0.13 (0.13)	0.39	0.09 (0.18)	0.80	0.009 (0.15)	0.99	0.07 (0.15)	0.57	0.11 (0.13)	0.49	0.07 (0.12)	0.47
Time (Ref: baseline)														
One month	0.38 (0.16)	0.018	0.09 (0.04)	0.02	0.06 (0.04)	0.13	0.02 (0.04)	0.62	0.04 (0.04)	0.31	0.03 (0.04)	0.45	0.03 (0.04)	0.45
Six months	0.25 (0.16)	0.12	0.02 (0.04)	0.56	0.06 (0.04)	0.13	0.07 (0.04)	0.05	0.06 (0.04)	0.16	0.05 (0.04)	0.29	0.04 (0.04)	0.29
Group × Time														
EXP vs. UC at one month	3.15 (0.230)	<0.001	0.64 (0.05)	<0.001	0.59 (0.06)	<0.001	0.45 (0.05)	<0.001	0.55 (0.06)	<0.001	0.76 (0.06)	<0.001	0.77 (0.06)	<0.001
EXP vs. UC at six months	3.20 (0.23)	<0.001	0.60 (0.05)	<0.001	0.59 (0.05)	<0.001	0.43 (0.05)	<0.001	0.50 (0.06)	<0.001	0.78 (0.06)	<0.001	0.78 (0.06)	<0.001
Intercept	10.88 (2.15)	<0.001	2.88 (0.38)	<0.001	2.84 (0.46)	<0.001	2.29 (0.43)	<0.001	2.54 (0.32)	<0.001	2.42 (0.39)	<0.001	2.18 (0.388)	<0.001
$\hat{\sigma}_{st}^2$ (patients)	1.91 (0.62)	0.003	0.11 (0.03)	0.002	0.20 (0.06)	<0.001	0.13 (0.04)	0.002	0.15 (0.04)	<0.001	0.08 (0.03)	0.007	0.09 (0.03)	0.003
$\hat{\sigma}_{sc}^2$ (centers)	15.16 (0.94)	<0.001	0.41 (0.03)	<0.001	0.61 (0.04)	<0.001	0.57 (0.04)	<0.001	0.21 (0.02)	<0.001	0.42 (0.030)	<0.001	0.42 (0.03)	<0.001

Note. UC = usual care group. EXP = experimental group. MARS = Medication Adherence Rating Scale. INT = intention. PBC = Perceived

behavioral control. SRBAI = Self-report Behavioral Automaticity Index. SM = Self-monitoring. ACP = Action planning. CP = Coping planning.

ADR = Adverse drug reaction.

Table 4: Three-level Multiple Linear Regression Models Predicting Beliefs about Medication, Mania Symptoms, Severity of Illness, Depression, and Quality of Life

Variable	BMQ specific necessity		BMQ specific concerns		YMRS		CGI-BP-S		MARDS		QoL.BD		ADR	
	<i>B</i> ( <i>SE</i> )	<i>p</i> - value	<i>B</i> ( <i>SE</i> )	<i>p</i> - value	<i>B</i> ( <i>SE</i> )	<i>p</i> - value	<i>B</i> ( <i>SE</i> )	<i>p</i> - value	<i>B</i> ( <i>SE</i> )	<i>p</i> - value	<i>B</i> ( <i>SE</i> )	<i>p</i> - value	<i>B</i> ( <i>SE</i> )	<i>p</i> - value
<b>Group (Ref: UC)</b>	0.02 (0.58)	0.97	-0.20 (0.78)	0.80	-0.10 (0.44)	0.81	-0.08 (0.16)	0.62	-0.48 (1.26)	0.71	1.21 (1.07)	0.26	0.08 (0.11)	0.46
<b>Time (Ref: baseline)</b>														
<b>One month</b>	0.07 (0.12)	0.59	-0.18 (0.19)	0.35	-0.02 (0.18)	0.91	0.01 (0.03)	0.81	-0.45 (0.23)	0.055	0.27 (0.37)	0.46	0.10 (0.07)	0.15
<b>Six months</b>	0.54 (0.12)	<0.001	-0.24 (0.19)	0.21	-0.04 (0.01)	<0.001	0.03 (0.03)	0.33	-0.60 (0.24)	0.012	0.031 (0.37)	0.93	0.16 (0.14)	0.25
<b>Group × Time</b>														
<b>EXP vs. UC at one month</b>	4.51 (0.17)	<0.001	-6.67 (0.27)	<0.001	-3.1 (0.01)	<0.001	-0.26 (0.05)	<0.001	-4.70 (0.33)	<0.001	0.93 (0.55)	0.09	0.14 (0.09)	0.12
<b>EXP vs. UC at six months</b>	4.83 (0.17)	<0.001	-6.82 (0.28)	<0.001	-5.39 (0.01)	<0.001	-0.53 (0.05)	<0.001	-4.54 (0.33)	<0.001	1.40 (0.52)	0.025	0.20 (0.12)	0.09
<b>Intercept</b>	15.39 (1.31)	<0.001	10.47 (1.72)	<0.001	13.41 (1.34)	<0.001	5.00 (0.373)	<0.001	24.09 (2.69)	<0.001	44.99 (4.54)	<0.001	6.68 (0.33)	<0.001
<b><math>\hat{\sigma}_{st}^2</math> (patients)</b>	2.25 (0.62)	<0.001	4.12 (1.12)	<0.001	1.20 (0.36)	0.002	0.165 (0.048)	<0.001	10.88 (2.99)	<0.001	3.92 (1.92)	0.051	0.512 (0.13)	<0.001


$\hat{\sigma}_{sc}^2$	4.63	<0.001	7.18	<0.001	6.35	<0.001	0.384	<0.001	19.36	<0.001	71.19	<0.001	0.42	<0.001
(centers)	(0.31)		(0.52)		(0.36)		(0.025)		(1.27)		(4.45)		(0.11)	

*Note.* UC = usual care group. EXP = experimental group. BMQ = Beliefs about Medicines Questionnaire. YMRS = Young Mania Rating Scale.

CGI-BP-S = Clinical Global Impressions-Bipolar-Severity of Illness. MARDS = Montgomery Åsberg Depression Rating Scale. QoL.BD =

Quality of Life in Bipolar Disorder scale. ADR = Adverse drug reaction.

**Figure 1: Flow of Participants through the Trial**





#### a) Psychoeducation

At least one family member (i.e., a spouse, partner, parent, or sibling) in the experimental (EXP) group was invited to attend two sessions of group psychoeducation in the outpatient clinic. Each session was conducted by a board-certified psychiatrist and lasted 70 minutes, with a 15-minute break. At the sessions, the family members and the patients were given information about the aetiology, symptoms, and prognosis of BD, as well as mood stabilizers, antidepressants, and their possible side effects. Each family member was also provided with information about the importance of MA and the risks of discontinuing the medication. At the end of the sessions, the family members were given a booklet providing information about BD and possible drug treatments.

#### b) Motivational interviewing (MI)

The goal of the MI sessions was to reduce resistance and overcome ambivalence about taking medication. Patients in the EXP group attended three sessions over 1 month, each lasting 40 to 65 minutes. All of the sessions were held in a quiet, private, and comfortable setting inside the outpatient clinics. Seven trained and registered health psychologists delivered the individual counseling sessions (all of whom had over 5 years of experience working in psychiatric settings). The health psychologists were trained in MI techniques by an experienced MI trainer (the first author) in two weeks that focused on didactic and experimental learning techniques. The goals of these training sessions were to convey the spirit, processes, and skills of MI in an effort to help the health psychologists to conduct the MI competently. The first week provided an introduction to MI and the application of MI to clinical training. The second week focused on advanced clinical training, supervisor training, and training for trainers. The content of the sessions was selected based on Motivational Interviewing Training New Trainers Manual (<http://www.motivationalinterview.org>).

Once trained, the facilitators used the following MI techniques to help the patients to take their medication regularly: Open-ended questions, rolling with resistance, setting agenda and eliciting self-motivational statements, change talk and affirmations.

The first session was designed to prepare the patient for the MI. The facilitator introduced themselves to the patients and assured them that the conversations would be kept private. Afterward, the facilitator encouraged the patients to discuss and list any concerns that may interfere with their willingness and motivation to receive psychiatric treatment and take medication by asking some basic questions (such as “*What do you call your problem?*”, “*What do you think has caused your problem?*”, and “*What do you fear most about your illness?*”). Facilitators also provided information on the medication that patients should take (dose and timing, adverse effects, contradictions, and treatment process).

During the second session, the facilitators tried to persuade the patients to commit to change and adhere to the treatment. Open-ended questions (e.g., “*So how have things gone this week?*” and “*How have you been feeling?*”) were used to assess new stressors and changes in the environment that were likely to affect the patients. The facilitators also inquired about patients’ adherence and the response to the medication and helped each patient to weigh up the perceived costs and benefits of taking medication (e.g., “*What do you see as the positive and negative consequences of taking medication?*”). The patient’s readiness to change was rated on a scale from 1 (I’m not willing to change) to 10 (I will do anything that I need to change). The importance of taking medicine regularly was also raised by the facilitators and was rated by the patients on a scale from 0 (least important) to 10 (most important). These questions were followed up by open-ended questions that invited patients to further elaborate on their choices (e.g., “*Why did you choose a (current number) instead of a (lower number)?*”, “*What would need to*

*happen to make it a (higher number)?”). The patients were also encouraged to think about what it would be like to make the change by imagining future situations; (e.g., “If you were successful in taking medicine regularly, how would things be different?”* Finally, the facilitators measured and discussed patients’ confidence in their ability to change by asking questions such as “*On a scale from 0 to 10, where 10 is the most confident and 0 is the least, what number would you give for how confident you are that you could taking medicine regularly?*”

The third session addressed potential obstacles to MA. The facilitator helped the patients to review their progress, and sought to renew and reinforce their motivation. Patients were helped to identify obstacles that might prevent them from taking medication, to identify strategies to overcome obstacles that arise, and to build self-efficacy. In addition, patients were invited to set goals and make plans to support desired changes. Worksheets were given to the patients that encouraged them to identify things that they would need to do to achieve a given goal. The facilitators also encouraged the patients to create an action plan by specifying where, when and how they would take their medication. Patients were also asked to anticipate situations in which it might be difficult to take medication and were encouraged to identify strategies to overcome these barriers (coping planning).

In addition to the MI sessions for the patients, a single MI session was conducted for the family members of the patients in the EXP group. The same facilitators contacted each family member by telephone and invited them to attend a single session. At the beginning of the session, the family members were encouraged to express their feelings about medications and their role in supporting their family members to take their medication regularly was discussed. Barriers and facilitators to behavior change were also explored and the facilitators helped the family members to identify the pros and cons

of helping the patients to take their medication regularly. The family members rated the patients' level of commitment and likelihood of success on a 0-10 scale. Family members were encouraged to imagine the patients in the future with and without change. Finally, family members were asked to help their patients to use reminders (such as phone alarm or sticky notes) to improve their MA.

Table S1. Descriptive statistics for global measures of Motivational Interview Treatment Integrity (MITI), behavior counts, summary scores, and interrater reliability

Measures	Mean $\pm$ SD	Minimum	Maximum	ICC
<b>Global measures</b>				
Evocation	3.99 (0.65)	2	5	0.69
Collaboration	3.31 (0.32)	2	5	0.71
Autonomy/support	4.02 (0.51)	1	5	0.73
Direction	3.99 (0.53)	1	5	0.79
Empathy	4.48 (0.50)	1	5	0.70
<b>Behavior counts</b>				
Giving Information	0.34 (0.40)	0		0.81
MI-Adherent	5.47 (2.64)	0	18	0.92
MI-Non-Adherent	0.88 (0.93)	0	5	0.87
Closed Questions	12.83 (8.01)	0	32	0.76
Open Questions	8.19 (4.03)	0	30	0.81
Simple Reflections	11.61 (6.12)	0	49	0.68
Complex Reflections	100.00 (5.81)	1	30	0.80
<b>Summary scores</b>				
Global Spirit Rating	3.99 (0.47)	2.11	4.81	0.79
Percent Complex Reflections	50.38 (16.88)	10.01	100.00	0.76
Percent Open Questions	60.73 (15.90)	20.17	100.00	0.81
Reflection-to-Question Ratio	2.55 (2.13)	0.37	19.46	0.77
Percent MI Adherent	96.68 (6.25)	50.00	100.00	0.83

*Note.* MI = motivational interviewing. MITI = Motivational Interview Treatment Integrity. ICC = intraclass correlation coefficient; used for testing inter-rater reliability between two raters.

Table S2. Three-level Multiple Linear Regression Models Predicting Serum Levels

Variable	Serum Lithium level		Serum Carbamazepine level		Serum Sodium Valproate level	
	<i>B (SE)</i>	<i>p</i> -value	<i>B (SE)</i>	<i>p</i> -value	<i>B (SE)</i>	<i>p</i> -value
Group (Ref: UC)	0.02 (0.04)	0.62	0.08 (0.32)	0.80	0.69 (2.14)	0.74
Time (Ref: baseline)						
One month	0.04 (0.01)	0.002	0.19 (0.11)	0.07	1.94 (0.52)	<0.001
Six months	-0.06 (0.01)	<0.001	-0.26 (0.11)	0.016	2.70 (0.52)	<0.001
Group × Time						
EXP vs. UC at one month	0.15 (0.02)	<0.001	1.61 (0.15)	<0.001	3.62 (0.73)	<0.001
EXP vs. UC at six months	0.20 (0.02)	<0.001	1.40 (0.16)	<0.001	5.28 (0.74)	<0.001
Intercept	0.80 (0.09)	<0.001	6.01 (0.73)	<0.001	44.54 (8.56)	<0.001
$\hat{\sigma}_{st}^2$ (patients)	0.04 (0.003)	<0.001	0.66 (0.18)	<0.001	18.71 (8.13)	0.022
$\hat{\sigma}_{sc}^2$ (centers)	0.02 (0.002)	<0.001	1.06 (0.10)	<0.001	256.87 (15.35)	<0.001

Note. UC = usual care group. EXP = experimental group. ADR = Adverse drug reaction.

Table S3: Direct and Mediated Effects of Group on Medication Adherence and Quality of Life (QoL)

Outcome	Time (Month)	Mediator	Coefficient (SE)			
			A. Intervention effect on outcome	B. Intervention effect on mediator	C. Mediator effect on outcome	Mediated effect (=B*C)
			3.15 (0.23)**			
		BMQ necessity		4.33 (0.17)**	0.13 (0.01)**	0.55** (0.04)
		BMQ concerns		-6.67 (0.27)**	-0.07 (0.01)**	0.45** (0.08)
		PBC		0.59 (0.06)**	0.13 (0.10)	0.08 (0.06)
	1	Intention		0.60 (0.05)**	0.432 (0.12)**	0.26 (0.07)**
		Self-monitoring		0.55 (0.06)**	0.77 (0.110)**	0.42 (0.08)**
		Action planning		0.76 (0.06)**	0.54 (0.10)**	0.41 (0.08)**
		Coping planning		0.77 (0.06)**	0.56 (0.08)**	0.43 (0.07)**
		SRBIA		0.45 (0.05)**	0.11 (0.11)	0.05 (0.05)
			3.20 (0.23)**			
	6	BMQ necessity		4.77 (0.17)**	0.12 (0.01)**	0.57 (0.05)**
		BMQ concerns		-6.75 (0.28)**	-0.06 (0.01)**	0.42 (0.07)**
		PBC		0.58 (0.05)**	0.16 (0.10)	0.09 (0.06)

		Intention	0.60 (0.05)**	0.478 (0.11)**	0.29 (0.07)**
		Self monitoring	0.50 (0.06)**	0.79 (0.11)**	0.40 (0.07)**
		Action planning	0.78 (0.06)**	0.54 (0.10)**	0.42 (0.08)
		Coping planning	0.78 (0.06)**	0.52 (0.09)**	0.40 (0.08)**
		SRBIA	0.43 (0.05)**	0.142 (0.10)	0.06 (0.04)
QoL.BD	1	Medication adherence	0.93 (0.55)**	3.15 (0.23)**	0.04 (0.02)**
	6	Medication adherence	1.17 (0.52)*	3.20 (0.23)**	0.23 (0.02)**

BMQ= Beliefs about Medicines Questionnaire; PBC= Perceived behavioral control; SRBIA= Self-report Behavioral Automaticity Index; QoL.BD= Quality of Life in Bipolar Disorder scale. \* $p < 0.05$ , \*\* $p < 0.01$